DWC 20162
Alternative Names: DWC-20162Latest Information Update: 28 Dec 2019
At a glance
- Originator Daewoong Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2019 No recent reports of development identified for phase-I development in Unspecified(In volunteers) in South Korea
- 20 Dec 2016 Daewoong Pharmaceuticals completes a phase I trial in Healthy volunteers in South Korea (unspecified route) (NCT02952755)
- 16 Dec 2016 Daewoong Pharmaceuticals plans a phase I trial in Healthy volunteers in South Korea (NCT02952755)